Abstract
Tumour illness and its resistance against existing anticancer therapies pose a serious health concern globally despite the progressive advancement of therapeutic options. The prevailing treatment of HCC using numerous antitumor agents has inflated long-lived complete remissions, but a percentage of individuals still die due to disease recurrence, indicating a need for further exploration of possible anti-tumour regimes. We aim to boost the effectiveness of the HCC treatment by conducting current investigations evaluating the effect of arsenic trioxide (ATO) with different herbal compounds like quercetin and aloe-emodin against liver tumour via inhibition of telomerase, a pro-cancer enzyme. The anticancer activity of ATO with herbal compounds was investigated in human control liver cell line (Wrl-68) and cancer liver cell line (HepG2) at different time intervals. Viability and cytotoxicity in response to combinatorial drugs were assessed in vitro by trypan blue dye exclusion assay and MTT and WST assay. Apoptosis was analysed by annexin V/PI assay, and the expression of telomerase and apoptosis-regulating proteins was evaluated by immunoblotting and qRT-PCR. Arsenic trioxide in combination with quercetin and aloe-emodin reduced cell viability in cancerous cells compared to normal cells by inducing apoptosis, downregulating telomerase and Bcl-2 (anti-apoptotic protein) and upregulating the expression of Bax (pro-apoptotic protein). ATO exhibited significant anticancer effects due to the synergistic effects of quercetin and aloe-emodin in liver tumour cells. The current study data collectively suggest that a successful inhibition of cancer growth by the combination of ATO and tested herbal medicines against liver tumour growth is via the inhibition of telomerase activity.
Graphical Abstract
Similar content being viewed by others
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Code Availability
Not applicable.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Bruix J, Boix L, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer cell 5(3):215–219. https://doi.org/10.1016/s1535-6108(04)00058-3
Ringelhan M, McKeating JA, Protzer U (2017) Viral hepatitis and liver cancer. Philos Trans R Soc Lond Ser B Biol Sci 372(1732):20160274. https://doi.org/10.1098/rstb.2016.0274
Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr (2016) Hepatocellular carcinoma: a review. J Hepatocellular Carcinoma 3:41–53. https://doi.org/10.2147/JHC.S61146
Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A (2017) Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 9(21):907–920. https://doi.org/10.4254/wjh.v9.i21.907
Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5):735–741. https://doi.org/10.1038/sj.leu.2402106
Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ (2011) Arsenic exposure and toxicology: a historical perspective. Toxicol Sci 123:305–332. https://doi.org/10.1093/toxsci/kfr184
Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48(Suppl 1):S72–S76. https://doi.org/10.1007/s002800100309
Chaudhary A, Haque R (2021) The healing art of arsenic in various malignancies. In: Kumar N. (eds) Arsenic toxicity: challenges and solutions. Springer, Singapore. https://doi.org/10.1007/978-981-33-6068-6_12
Nafiujjaman M, Nurunnabi M, Saha SK, Jahan R, Lee YK, Rahmatullah M (2015) Anticancer activity of Arkeshwara Rasa - a herbo-metallic preparation. Ayu 36(3):346–350. https://doi.org/10.4103/0974-8520.182757
Chen X, Hong Y, Zheng P, You X, Feng J, Huang Z, Wang Y (2020) The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China. Cancer 126(2):311–321. https://doi.org/10.1002/cncr.32519
Lengfelder E, Hofmann WK, Nowak D (2012) Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 26(3):433–442. https://doi.org/10.1038/leu.2011.245
Jafri MA, Ansari SA, Alqahtani MH, Shay JW (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 8(1):69. https://doi.org/10.1186/s13073-016-0324-x
Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P (2018) Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci 25(1):22. https://doi.org/10.1186/s12929-018-0422-8
Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66(3):407–425. https://doi.org/10.1128/mmbr.66.3.407-425.2002
Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K (2020) TERT-regulation and roles in cancer formation. Front Immunol 11:589929. https://doi.org/10.3389/fimmu.2020.589929
Holysz H, Lipinska N, Paszel-Jaworska A, Rubis B (2013) Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol: J Int Soc Oncodev Biol Med 34(3):1371–1380. https://doi.org/10.1007/s13277-013-0757-4
Autexier C (1999) Telomerase as a possible target for anticancer therapy. Chem Biol 6(11):R299–R303. https://doi.org/10.1016/s1074-5521(99)80122-7
Meyerson M (2000) Role of telomerase in normal and cancer cells. J Clin Oncol: Off J Am Soc Clin Oncol 18(13):2626–2634. https://doi.org/10.1200/JCO.2000.18.13.2626
In der Stroth L, Tharehalli U, Günes C, Lechel A (2020) Telomeres and telomerase in the development of liver cancer. Cancers 12(8):2048. https://doi.org/10.3390/cancers12082048
Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV (2001) Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Investig 108(10):1541–1547. https://doi.org/10.1172/JCI14064
Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, Zhang SF, Tang MK, Sun JN, Ko KM (2014) Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Evid Based Complement Alternat Med: Ecam 2014:525340. https://doi.org/10.1155/2014/525340
Yuan H, Ma Q, Ye L, Piao G (2016) The traditional medicine and modern medicine from natural products. Molecules (Basel Switzerland) 21(5):559. https://doi.org/10.3390/molecules21050559
Safarzadeh E, SandoghchianShotorbani S, Baradaran B (2014) Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 4(Suppl 1):421–427. https://doi.org/10.5681/apb.2014.062
Baláž P, Sedlák J (2010) Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins 2(6):1568–1581. https://doi.org/10.3390/toxins2061568
Mukherjee PK (2019) Antiviral evaluation of herbal drugs. Qual Control Eval Herb Drugs 599–628. https://doi.org/10.1016/B978-0-12-813374-3.00016-8
Wu Q, Lin WD, Liao GQ, Zhang LG, Wen SQ, Lin JY (2015) Antiproliferative effects of cinobufacini on human hepatocellular carcinoma HepG2 cells detected by atomic force microscopy. World J Gastroenterol 21(3):854–861. https://doi.org/10.3748/wjg.v21.i3.854
Ganesan K, Xu B (2017) telomerase inhibitors from natural products and their anticancer potential. Int J Mol Sci 19(1):13. https://doi.org/10.3390/ijms19010013
Vafadar A, Shabaninejad Z, Movahedpour A, Fallahi F, Taghavipour M, Ghasemi Y, Akbari M, Shafiee A, Hajighadimi S, Moradizarmehri S, Razi E, Savardashtaki A, Mirzaei H (2020) Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci 10:32. https://doi.org/10.1186/s13578-020-00397-0
Gibellini L, Pinti M, Nasi M, De Biasi S, Roat E, Bertoncelli L, Cossarizza A (2010) Interfering with ROS metabolism in cancer cells: the potential role of quercetin. Cancers 2(2):1288–1311. https://doi.org/10.3390/cancers2021288
Reyes-Farias M, Carrasco-Pozo C (2019) The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci 20(13):3177. https://doi.org/10.3390/ijms20133177
Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A (2001) Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Can Res 61(14):5432–5440
Sadaf N, Kumar N, Ali M, Ali V, Bimal S, Haque R (2018) Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci 205:9–17. https://doi.org/10.1016/j.lfs.2018.05.006
Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, Cheng L, Liu M, Wang C, Wu N, Zhao X, Zhang Y, Liao J, Chu E, Lin X (2014) Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis. Oncol Res 21(5):247–259. https://doi.org/10.3727/096504014X13946388748910
Yedjou C, Tchounwou P, Jenkins J, McMurray R (2010) Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 3:28. https://doi.org/10.1186/1756-8722-3-28
Ghaffari SH, Momeny M, Bashash D, Mirzaei R, Ghavamzadeh A, Alimoghaddam K (2012) Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 17(4):198–206. https://doi.org/10.1179/1607845412Y.0000000008
Kim W, Ludlow AT, Min J, Robin JD, Stadler G, Mender I, Lai TP, Zhang N, Wright WE, Shay JW (2016) Regulation of the human telomerase gene TERT by telomere position effect-over long distances (TPE-OLD): implications for aging and cancer. PLoS Biol 14(12):e2000016. https://doi.org/10.1371/journal.pbio.2000016
Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, Ségal-Bendirdjian E (2005) Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 19(10):1806–1811. https://doi.org/10.1038/sj.leu.2403923
Funding
The work was supported by grant No. EMR/2017/004171 from DST-SERB (Science and Engineering Research Board) India and the Council of Scientific and Industrial Research (CSIR-UGC) in the form of a fellowship to the first author.
Author information
Authors and Affiliations
Contributions
Rizwanul Haque contributed to the study conception and design. Material preparation and data collection were performed by Archana Chaudhary. Formal analysis and investigation were carried out by Archana Chaudhary, Sadhan Kumar Bhardwaj, Azmi Khan, Amrita Srivastava, Kislay Kumar Sinha, Mehboob Ali and Rizwanul Haque. Archana Chaudhary, Sadhan Kumar Bhardwaj and Azmi Khan drafted the manuscript. Rizwanul Haque and Mehboob Ali reviewed and edited the previous version of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chaudhary, A., Bhardwaj, S.K., Khan, A. et al. Combinatorial Effect of Arsenic and Herbal Compounds in Telomerase-Mediated Apoptosis Induction in Liver Cancer. Biol Trace Elem Res 201, 3300–3310 (2023). https://doi.org/10.1007/s12011-022-03430-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12011-022-03430-0